Isofol Medical AB (publ) (STO:ISOFOL)
Sweden · Delayed Price · Currency is SEK 0.5955
-0.0280 (-4.49%)
Feb 5, 2026, 5:29 PM CET
Isofol Medical AB Company Description
Isofol Medical AB (publ) operates as a clinical stage biotech company.
The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer.
Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.
Isofol Medical AB (publ)
| Country | Sweden |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Petter Lindqvist |
Contact Details
Address: Biotech Center Gothenburg, 413 46 Sweden | |
| Phone | 46 0 31 13 73 31 |
| Website | isofolmedical.com |
Stock Details
| Ticker Symbol | ISOFOL |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0009581051 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Petter Segelman Lindqvist | Chief Executive Officer |
| Dr. Roger Tell M.D., Ph.D. | Chief Medical Officer |
| Margareta Hagman M.B.A. | Chief Financial Officer |
| John Proffett | Business Development and Chief Business Officer |